- Home
- CLLS vs GLUE Comparison
CLLS vs GLUE Comparison
Compare CLLS & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | GLUE |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 308.8M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | GLUE |
|---|---|---|
| Price | $4.98 | $16.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | 124.5K | ★ 980.7K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $82,551,000.00 | ★ $181,538,000.00 |
| Revenue This Year | N/A | $66.94 |
| Revenue Next Year | $58.00 | N/A |
| P/E Ratio | ★ N/A | $64.10 |
| Revenue Growth | 129.04 | ★ 1112.27 |
| 52 Week Low | $1.10 | $3.50 |
| 52 Week High | $5.48 | $16.66 |
Technical Indicators
Market Signals| Indicator | CLLS | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 72.97 |
| Support Level | $4.90 | $13.27 |
| Resistance Level | $5.35 | $16.66 |
| Average True Range (ATR) | 0.28 | 1.02 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 85.56 | 88.50 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.